<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Pharmacology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1663-9812</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8419280</article-id>
    <article-id pub-id-type="publisher-id">746067</article-id>
    <article-id pub-id-type="doi">10.3389/fphar.2021.746067</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Pharmacology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ACNPD: The Database for Elucidating the Relationships Between Natural Products, Compounds, Molecular Mechanisms, and Cancer Types</article-title>
      <alt-title alt-title-type="left-running-head">Tan et al.</alt-title>
      <alt-title alt-title-type="right-running-head">ACNPD</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Tan</surname>
          <given-names>Xiaojie</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fu</surname>
          <given-names>Jiahui</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yuan</surname>
          <given-names>Zhaoxin</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn1">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Lingjuan</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="corresp" rid="c001">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fu</surname>
          <given-names>Leilei</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="corresp" rid="c001">*</xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1417152/overview"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><label><sup>1</sup></label>School of Life Science and Engineering, Southwest Jiaotong University, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
    <aff id="aff2"><label><sup>2</sup></label>Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, <addr-line>Shenyang</addr-line>, <country>China</country></aff>
    <aff id="aff3"><label><sup>3</sup></label>MOE Key Laboratory of Protein Sciences, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, <addr-line>Beijing</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p><bold>Edited by:</bold><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/565394/overview">Haiyang Yu</ext-link>, Tianjin University of Traditional Chinese Medicine, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p><bold>Reviewed by:</bold><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1192442/overview">Xiaoxiao Huang</ext-link>, Shenyang Pharmaceutical University, China</p>
        <p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1419594/overview">Xj He</ext-link>, Guangdong Pharmaceutical University, China</p>
        <p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1420839/overview">Yan Shen</ext-link>, Nanjing University, China</p>
      </fn>
      <corresp id="c001">*Correspondence: Leilei Fu, <email>leilei_fu@163.com</email>; Lingjuan Zhu, <email>zhulingjuanadele@163.com</email></corresp>
      <fn fn-type="other">
        <p>This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology</p>
      </fn>
      <fn fn-type="equal" id="fn1">
        <label>
          <sup>†</sup>
        </label>
        <p>These authors have contributed equally to this work</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <volume>12</volume>
    <elocation-id>746067</elocation-id>
    <history>
      <date date-type="received">
        <day>23</day>
        <month>7</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>10</day>
        <month>8</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2021 Tan, Fu, Yuan, Zhu and Fu.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>Tan, Fu, Yuan, Zhu and Fu</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p><bold>Objectives:</bold> Cancer is well-known as a collection of diseases of uncontrolled proliferation of cells caused by mutated genes which are generated by external or internal factors. As the mechanisms of cancer have been constantly revealed, including cell cycle, proliferation, apoptosis and so on, a series of new emerging anti-cancer drugs acting on each stage have also been developed. It is worth noting that natural products are one of the important sources for the development of anti-cancer drugs. To the best of our knowledge, there is not any database summarizing the relationships between natural products, compounds, molecular mechanisms, and cancer types.</p>
      <p><bold>Materials and methods:</bold> Based upon published literatures and other sources, we have constructed an anti-cancer natural product database (ACNPD) (<ext-link ext-link-type="uri" xlink:href="http://www.acnpd-fu.com/">http://www.acnpd-fu.com/</ext-link>). The database currently contains 521 compounds, which specifically refer to natural compounds derived from traditional Chinese medicine plants (derivatives are not considered herein). And, it includes 1,593 molecular mechanisms/signaling pathways, covering 10 common cancer types, such as breast cancer, lung cancer and cervical cancer.</p>
      <p><bold>Results:</bold> Integrating existing data sources, we have obtained a large amount of information on natural anti-cancer products, including herbal sources, regulatory targets and signaling pathways. ACNPD is a valuable online resource that illustrates the complex pharmacological relationship between natural products and human cancers.</p>
      <p><bold>Conclusion:</bold> In summary, ACNPD is crucial for better understanding of the relationships between traditional Chinese medicine (TCM) and cancer, which is not only conducive to expand the influence of TCM, but help to find more new anti-cancer drugs in the future.</p>
    </abstract>
    <kwd-group>
      <kwd>ACNPD</kwd>
      <kwd>natural products</kwd>
      <kwd>pharmacological mechanism</kwd>
      <kwd>database</kwd>
      <kwd>cancer</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>Introduction</title>
    <p>Cancer, with the continuously increasing morbidity and mortality, is the second most deadly disease in the world, which seriously threaten people’s life and health. (<xref rid="B11" ref-type="bibr">Fidler et al., 2017</xref>). At present, continuous proliferation, invasion and metastasis, angiogenesis and apoptosis resistance have been founded to be closely related to the occurrence and development of cancer (<xref rid="B16" ref-type="bibr">Hisano and Hla, 2019</xref>; <xref rid="B39" ref-type="bibr">Wimmer et al., 2020</xref>). For example, tumor metastasis is a common process in the development of malignant tumors, in which cancer cells undergo the invasion–metastasis cascade, including five main steps: leaving the primary lesion, passing through blood vessels, spreading through blood circulation and lymphatic circulation, or directly spreading through body cavity, continuing to proliferate and grow in other parts, and eventually forming colonization at a remote site of the body (<xref rid="B27" ref-type="bibr">Mittal, 2018</xref>). In this process, occurred autophagy and apoptosis inhibition may equip cancer cells with enhanced ability to divide and proliferate (<xref rid="B9" ref-type="bibr">Dower et al., 2018</xref>). In addition, abnormal metabolic and immune escape, as well as changes in the tumor microenvironment, are also considered to be crucial hallmarks of cancer (<xref rid="B26" ref-type="bibr">McGranahan et al., 2017</xref>; <xref rid="B6" ref-type="bibr">Counihan et al., 2018</xref>; <xref rid="B15" ref-type="bibr">Hinshaw and Shevde, 2019</xref>). Currently, many kinds of clinical treatments, including surgery, chemotherapy, radiotherapy, immunotherapy and gene therapy have been applied to treat cancer. (<xref rid="B10" ref-type="bibr">Fesnak et al., 2016</xref>; <xref rid="B3" ref-type="bibr">Chen and Mellman, 2017</xref>; <xref rid="B5" ref-type="bibr">Chen et al., 2019</xref>). However, the limited application scope and severe side effects restrain of above methods make the use of anticancer drugs crucial in treating cancer.</p>
    <p>Notably, natural products (referring to natural compounds derived from Traditional Chinese Medicine (TCM) plants and derivatives are not considered herein) constitute an important source of anti-cancer drugs, and about 50% of the anti-cancer drugs currently in use are directly or indirectly derived from natural products, including flavonoids, alkaloids and terpenoids and others (<xref rid="B30" ref-type="bibr">Mondal et al., 2019</xref>; <xref rid="B8" ref-type="bibr">Deng et al., 2020</xref>; <xref rid="B20" ref-type="bibr">Kopustinskiene et al., 2020</xref>). Over the past two decades, a large number of natural anti-cancer products have been extracted, isolated and purified from Chinese herbal medicines. For example, paclitaxel, extracted from the bark of <italic>Taxus chinensis</italic>, is recognized as one of the most potent and broad-spectrum anti-cancer drugs especially for advanced, metastatic ovarian cancer, breast cancer, lung cancer (<xref rid="B1" ref-type="bibr">Abu Samaan et al., 2019</xref>; <xref rid="B7" ref-type="bibr">de Goeje et al., 2019</xref>; <xref rid="B46" ref-type="bibr">Zhu and Chen, 2019</xref>; <xref rid="B23" ref-type="bibr">Lau et al., 2020</xref>). Recently, accumulating evidences have shown that compounds derived from natural products could regulate various targets and signaling pathways and displayed great therapeutic potential in cancer. Curcumin, a polyphenolic compound mainly extracted from <italic>Curcuma longa, Curcuma zedoaria and Acorus calamus</italic> L., has been shown to induce autophagy through 5'AMP-activated protein kinase (AMPK) activation, resulting in the degradation of Akt, thereby inhibiting cell proliferation and migration of human breast cancer MDA-MB-231 cells (<xref rid="B13" ref-type="bibr">Guan et al., 2016</xref>). Additionally, curcumin induces apoptosis and autophagy in human non-small cell lung cancer A549 cells by inhibiting the phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway (<xref rid="B24" ref-type="bibr">Liu et al., 2018</xref>). Berberine, an isoquinoline alkaloid, induces autophagic cell death in cancer cells by increasing the level of Glucose regulated protein 78 (GRP78) and enhancing its ability to bind to vacuolar protein sorting 34(VPS34) (<xref rid="B22" ref-type="bibr">La et al., 2017</xref>). Berberine also inhibits the epithelial mesenchymal transformation of mouse melanoma B16 cells through PI3K/Akt pathway (<xref rid="B21" ref-type="bibr">Kou et al., 2016</xref>). Moreover, ursolic acid, isolated from Spreng (bearberry), <italic>Rhododendron hymenanthes</italic> Makino, <italic>Eriobotrya japonica</italic>, etc., plays an anti-cancer role in human ovarian cancer cells through apoptosis induction, cell cycle arrest and down-regulation of PI3K/AKT pathway, which is mediated by reactive oxygen species (Ros) and matrix metalloprotein (MMP). Interestingly, monomer compounds isolated from natural products can also be used as lead compounds for the synthesis of anticancer drugs. Through structural modification, they eventually play an important role in the treatment of many malignant tumors such as breast cancer, cervical cancer and leukemia, and greatly promote the development of new candidate drugs. (<xref rid="B35" ref-type="bibr">Rodrigues et al., 2016</xref>; <xref rid="B37" ref-type="bibr">Spradlin et al., 2019</xref>; <xref rid="B38" ref-type="bibr">Wang et al., 2019</xref>; <xref rid="B32" ref-type="bibr">Patel et al., 2020</xref>).</p>
    <p>Currently, a few traditional Chinese medicine web servers are available online to facilitate resource search, such as and Traditional Chinese Medicine database (TCM-database) and Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP). However, few databases of natural anti-cancer products have been constructed, and the existing databases only constitute the framework of active ingredient-targets-disease, while no databases holds a systematic summary of the specific mechanism of natural products against cancer. (<xref rid="B44" ref-type="bibr">Zhang et al., 2019</xref>). Thus, we have constructed an online database, ACNPD, focusing on the information of compounds (referring to natural compounds derived from Traditional Chinese Medicine (TCM) plants) and their pharmacological mechanisms. ACNPD is expected to help deepen the understanding of the intricate molecular mechanism of natural products in treating cancer, with a view to providing new clues for the development of anticancer drugs.</p>
  </sec>
  <sec sec-type="materials|methods" id="s2">
    <title>Materials and Methods</title>
    <sec id="s2-1">
      <title>Data Collection and Integration</title>
      <p>ACNPD is a collection of anti-cancer compounds in traditional Chinese herbal medicine, which can be divided into chemical and pharmacological parts, especially focusing on the anti-cancer molecular mechanism of natural products. Markedly, considering the variety and complexity of natural products, the pharmacological mechanisms of the compounds in the database are supported not only by systematic <italic>in vivo</italic> and <italic>in vitro</italic> studies, such as targets, signaling pathways, validation of animal models, etc., essential <italic>in vitro</italic> cytotoxicity tests are also included. These information and data come from the related network database and the text mining of the published articles. The names of natural products, IUPAC names, SMILES and CAS numbers were obtained primarily by PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) and supplemented and verified by ChemicalBook (<ext-link ext-link-type="uri" xlink:href="https://www.chemicalbook.com/">https://www.chemicalbook.com/</ext-link>) and Reaxys (<ext-link ext-link-type="uri" xlink:href="http://new.reaxys.com">http://new.reaxys.com</ext-link>). The TCMSP database (<ext-link ext-link-type="uri" xlink:href="http://tcmspw.com/tcmsp.php">http://tcmspw.com/tcmsp.php</ext-link>), the Chemical composition database of natural products in China (<ext-link ext-link-type="uri" xlink:href="http://www.baidu.com/link?url=tfcfXcaZ7u8F_9o-Ieb1obNZlIIz2kI8TKTOuqMCaHkWO2Fr_nbFiqoy6A-OOOjL">pharmdata.ncmi.cn/cnpc/</ext-link>) are used to search and collect herbal sources of natural anticancer products. We retrieved and sorted the pharmacological information of the compounds from a series of databases such as PubMed, SciFinder and Web of Science, and finally integrated them into six categories: inhibition of proliferation, promotion of apoptosis, autophagy, necrosis, inhibition of invasion and molecular mechanism. In brief, ACNPD is a comprehensive, high-quality, freely available database of natural products against cancer (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
      <table-wrap id="T1" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Data source.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">Data field</th>
              <th align="center" rowspan="1" colspan="1">Data source</th>
              <th align="center" rowspan="1" colspan="1">Amount of data</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">Natural compounds</td>
              <td align="left" rowspan="1" colspan="1">ChemicalBook, PubMed, PubChem, SciFinder and Reaxys</td>
              <td align="center" rowspan="1" colspan="1">521</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Mechanisms</td>
              <td align="left" rowspan="1" colspan="1">PubMed, SciFinder and Web of Science</td>
              <td align="center" rowspan="1" colspan="1">1,593</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Diseases</td>
              <td align="left" rowspan="1" colspan="1">PubMed, SciFinder, TCGA, Text-mining and Web of Science</td>
              <td align="center" rowspan="1" colspan="1">10</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s2-2">
      <title>Web Server Generation</title>
      <p>ACNPD builds Apache network server (version 2.4, The Apache Software Foundation, Wakefield, MA, United States) based on Linux operating system, PHP (Versions 7.1, Zend Technologies, Cupertino, CA, United States) scripting language for MySQL (version 5.1.48-log, Oracle Corporation, Redwood Shores, CA, United States). As the background system of ACNPD database, the system or software used is not only free and open source, but also has good stability and high security. The database interface is built on Web technology, Including CSS (Cascading Style Sheets), HTML (Hypertext Markup Language) and JavaScript (Oracle Corporation, Redwood Shores, CA, United States). Adopt Web server technology to develop and serve Web applications. Currently, the ACNPD database supports retrieval by all major Web browsers.</p>
    </sec>
    <sec id="s2-3">
      <title>Web Server Construction and Structure</title>
      <p>The integrated anti-cancer natural product data is composed of two main EXCEL tables, which are basic chemical information and pharmacological mechanism, respectively. Name, IUPAC Name, SMILES, CAS number, and Herb source of each compound are included in chemical information. The IUPAC Name is the Name of the International Union of Pure and Applied Chemistry, standardizing the names of all compounds in order to convert them into structural formulas corresponding to natural products. Importantly, information about pharmacological mechanism is the focus of our work, which is classified into six categories, including inhibition of proliferation, induction of apoptosis, autophagy, necrosis, inhibition of invasion. The above data and information are obtained from the network database and text retrieval, with guaranteed accuracy. Of note, the two datasheets can be interchanged by hyperlinking to meet different retrieval needs of users.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3-1">
      <title>The Extracted Information of ACNPD</title>
      <p>ACNPD brings together the chemical information and pharmacological mechanism of anti-cancer natural products to elucidate the intricate relationship between anticancer active compounds in herbs and cancers (<xref ref-type="fig" rid="F1">Figure 1</xref>). Interestingly, we searched related literatures in PubMed, SciFinder and Web of science by text-mining, and classified the pharmacological contents in detail, focusing on the related target proteins and pathways. By contrast, given the large number of existing databases of compounds, such as PubChem, ChemicalBook and others, the chemical information of natural products in ACNPD provides only basic information, including the IUPAC Name, SMILES, CAS number, and herbal source. Hitherto, a wide variety of cancers have been uncovered. Focusing on the statistical data published by the World Health Organization's International Agency for Research on Cancer (IARC), considering morbidity and mortality, the final 10 cancer types were determined to be included in ACNPD, such as breast, cervical, ovarian, lung, gastric, liver, colorectal, prostate, leukemia, and melanoma. In addition, the 13 common cancers provided by The Cancer Genome Atlas (TCGA) database and the literature search results were also included as a reference condition (<xref ref-type="sec" rid="s9">Supplementary Table S1</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Currently, the database contains 521 compounds and most of them show anti-cancer activity against a variety of cancers. For example, berberine, an alkaloid that isolated from herbs such as <italic>Achyranthis Bidentatae radix</italic>; <italic>chelidonii herba</italic>; <italic>Coptidis Rhizoma</italic>, etc., displays activity against 10 cancer cells mentioned above (<xref rid="B45" ref-type="bibr">Zhao et al., 2017</xref>; <xref rid="B28" ref-type="bibr">Mohammadlou et al., 2021</xref>). Studies have shown that berberine inhibits proliferation of colon cancer cells by inhibiting the Wnt/β-catenin signaling pathway (<xref rid="B41" ref-type="bibr">Wu et al., 2012</xref>). In another study, Berberine was found to inhibit TNF-α-induced matrix metalloprotein 9 (MMP-9) and cell invasion through inhibiting activating protein-1 (AP-1) in MDA-MB-231 human breast cancer cells (<xref rid="B19" ref-type="bibr">Kim et al., 2008</xref>). Additionally, 153 compounds such as Licoricidin, Limonin and Wogonin have been found to have anti-cancer effects by affecting the corresponding signaling pathways, mainly involving the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway, PI3K/Akt/mTOR signaling, Wnt/β-catenin signaling pathway (<xref rid="B33" ref-type="bibr">Rasul et al., 2012</xref>; <xref rid="B18" ref-type="bibr">Ji et al., 2017</xref>; <xref rid="B4" ref-type="bibr">Chen et al., 2018</xref>). Compounds in ACNPD were subdivided into five categories according to different pharmacological mechanisms, among which 262 compound induced programmed cell death and 109 compound inhibited cell invasion.</p>
      <fig id="F1" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Database structure. ACNPD is composed of compounds, traditional Chinese medicine sources, cancer types, and regulatory mechanisms. The relationship between the four key modules in ACNPD are described. Notably, the yellow triangle area represents the basic chemical information and the green triangle area represents the pharmacological mechanism contents.</p>
        </caption>
        <graphic xlink:href="fphar-12-746067-g001"/>
      </fig>
      <fig id="F2" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Classification of compounds in the ACNPD. <bold>(A)</bold> Classified by cancer types: 521 compounds derived from natural products were involved in 10 cancer types and percentages, including: Breast, cervical, ovarian, lung, gastric, liver, colorectal, prostate, leukemia and melanoma. <bold>(B)</bold> Classified by pharmacological mechanisms: all compounds are classified into five groups according to text retrieval: proliferation inhibition, apoptosis, autophagy, necrosis, invasion inhibition. Note: Groups are marked with different colors. The percentage of compounds contained in each group is shown in the pie chart.</p>
        </caption>
        <graphic xlink:href="fphar-12-746067-g002"/>
      </fig>
    </sec>
    <sec id="s3-2">
      <title>Database Query</title>
      <p>We built a friendly web interface that allows users to easily search across multiple browsers. Users can obtain the desired results through fuzzy search as follows: 1. Enter the type of cancer (currently limited to the 10 mentioned above), and the results page displays the relevant natural product items with the links to access the basic chemical information and pharmacological mechanism. For example, users can query 164 compounds with anti-breast cancer activity by entering breast cancer. Click the desired compound arbitrarily, and the corresponding database number, Herb source, pharmacological activity and other information will be displayed. 2. Users can use ACNPD to query the mechanism information of natural products. For example, by entering the name of a compound or CAS number, users can obtain the corresponding anticancer mechanism of this compound and intuitively know whether the natural product can inhibit proliferation, inhibit invasion, and whether it is related to autophagy. The relevant content can be verified by the references we provide for more detailed information. (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
      <fig id="F3" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Interface of ACNPD website. Users can search the database in two ways and query the detailed information through a link. For example, users can query not only by entering a cancer type name (such as Breast cancer) as a keyword, but also by entering the name of a compound from a natural product for field retrieval (e.g., arctigenin). <bold>(A)</bold> Query Home Page; <bold>(B)</bold> Breast cancer Search Result; <bold>(C)</bold> Search Result of Compound Arctigenin; <bold>(D)</bold> Submit Interface.</p>
        </caption>
        <graphic xlink:href="fphar-12-746067-g003"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>Cancer, also known as malignant tumor, is characterized by cells with abnormal proliferation, which is caused by mutated genes generated by external and internal factors. Hitherto, malignant tumors have been threatening human health in modern society. Recently, with the continuous upgrading of tumor biology and the emergence of drug problems such as anti-cancer drug resistance in clinical use, it is urgent to develop novel anti-cancer drugs. Notably, natural products, with their potent anti-cancer effectiveness and abundant resources, have become the top priority of anti-cancer drug research and development.</p>
    <p>Accumulating evidence has indicated that small-molecule compounds derived from natural plant products inhibit cell proliferation, metastasis, and invasion, regulate cell cycle, and induce cell apoptosis in various types of cancer through different targets and signaling pathways. For example, a large group of natural products, flavonoids, display pro-apoptosis effect, with Genistein, which acts on the p53 non-apoptotic pathway, and quercetin, which acts on the cytochrome C pathway. (<xref rid="B36" ref-type="bibr">Safarzadeh et al., 2014</xref>; <xref rid="B12" ref-type="bibr">George et al., 2018</xref>). Resveratrol inhibits the metastasis of cancer cells by down-regulating the expression of MMP-2, 9 by inhibiting the c-Jun N-terminal kinase (JNK) pathway (<xref rid="B2" ref-type="bibr">Bae et al., 2017</xref>). Quercetin, shikonin, and nobiletin are also demonstrated to inhibit cancer metastasis through suppressing MMP. (<xref rid="B17" ref-type="bibr">Jang et al., 2014</xref>). In addition, many compounds, including evodiamine, oridonin and jaceosidin, act on the PI3K/Akt pathway, which is a common inflammatory and cancer transformation pathway. Phosphorylation of its substrate GSK-3β can inhibit the translocation of Bax and the degradation of Bcl-2, leading to apoptosis inhibition of cancer cells (<xref rid="B29" ref-type="bibr">Mohan et al., 2016</xref>; <xref rid="B40" ref-type="bibr">Woo and Kwon, 2016</xref>). Arctigenin, a lignanolids isolated from <italic>Arctium lappa</italic> L. inhibits the angiogenesis through downregulating MMP-2, MMP-9 and heparinase (<xref rid="B25" ref-type="bibr">Lou et al., 2017</xref>). In recent years, emerging research suggested that the number and diversity of therapeutic targets in cancer far exceeds the oncogenes identified so far, expanding the understanding of cancer biology and corresponding therapeutic strategies (<xref rid="B14" ref-type="bibr">Hahn et al., 2021</xref>). In addition to traditional anti-cancer targets, natural products have also been found to act on several emerging targets, including targeted inhibition of histone deacetylase (HDAC), targeted inhibition of heat shock protein HSP90, targeted glycolysis, and others (<xref rid="B31" ref-type="bibr">Palermo et al., 2005</xref>; <xref rid="B42" ref-type="bibr">Yoon and Eom, 2016</xref>). Although natural products have unique anti-cancer properties, there is a lag in the construction of relevant mechanism databases, thus, the development of ACNPD has broad application prospects and far-reaching practical significance.</p>
    <p>Importantly, ACNPD is an online webserver that provides users with the pharmacological mechanisms of natural anti-cancer products. The database contains 10 common cancer types, 521 compounds, 131 pharmacological pathways, including PI3K/Akt, STAT3, PI3K/Akt/mTOR, Wnt/β-catenin and other signaling pathways. The web interface allows users to query related information in a variety of ways, providing basic chemical information, such as IUPAC Name and CAS number, and detailed pharmacological mechanisms of natural compounds. Importantly, we divided the pharmacological effects in a more detailed way and provided the signaling pathways involved, which is a supplement to the previous database and helps users to obtain information quickly and intuitively. At present, ACNPD only contains 10 common cancer types with high incidence, and the number of compounds remains to be expanded. With the extraction and separation of more natural products and the in-depth study of their pharmacological mechanism, we will continue to expand the scope of cancer and add new natural compounds to update ACNPD.</p>
    <p>In summary, we believe that ACNPD is a valuable database to fill the gaps between the therapeutic mechanism and natural anti-cancer products. The database is expected to help study the biological function and pharmacological activity of natural products in cancer, break the development bottleneck between natural anticancer compounds and modern anticancer drugs, and usher in a promising prospect for the innovative anticancer drugs.</p>
  </sec>
</body>
<back>
  <ack>
    <p>We are grateful to <bold>Prof. Haoyang Cai</bold> (Sichuan University) for his critical review on this manuscript.</p>
  </ack>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>XT, JF contributed to conception, design, data interpretation, and drafting of manuscript; ZY contributed to data collection. LF, LZ gave guidance and support to the project. All authors contributed to the article and approved the submitted version.</p>
  </sec>
  <sec id="s7">
    <title>Funding</title>
    <p>This work was supported by Natural Science Foundation of China (Grant No. 31970374),Research Foundation for Administration of traditional Chinese Medicine of Sichuan Province (Grant No. 2020HJZX002), and Applied Basic Research Programs of Science and Technology Department of Sichuan Province (Grant No. 2020YJ0285).</p>
  </sec>
  <sec sec-type="COI-statement" id="s8">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec id="s9" sec-type="disclaimer">
    <title>Publisher’s Note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
  <sec id="s10">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.746067/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.746067/full#supplementary-material</ext-link>
</p>
    <supplementary-material content-type="local-data" id="SM1">
      <media xlink:href="Table1.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <sec id="s11">
    <title>Abbreviations</title>
    <p>ACNPD, Anti-cancer natural product database; AP-1, activating protein-1; GRP78, Glucose regulated protein 78; HDAC, Histone deacetylase; IUPAC, International Union of Pure and Applied Chemistry chemical nomenclature; JNK, c-Jun N-terminal kinase; mTOR, mammalian target of rapamycin; MMP, matrix metalloprotein; MMP-9, Matrix metalloprotein 9; PI3K, phosphatidylinositol 3 kinase; ROS, Reactive oxygen species; STAT3, Signal Transducer and Activator of Transcription 3; TCGA, The Cancer Genome Atlas; TCM database, Traditional Chinese Medicine database; TCM, Traditional Chinese medicine; TCMSP, Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform; TNF-α, Tumor necrosis factor-α; VPS34, vacuolar protein sorting 34.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu Samaan</surname><given-names>T. M.</given-names></name><name><surname>Samec</surname><given-names>M.</given-names></name><name><surname>Liskova</surname><given-names>A.</given-names></name><name><surname>Kubatka</surname><given-names>P.</given-names></name><name><surname>Büsselberg</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer</article-title>. <source>Biomolecules</source>
<volume>9</volume> (<issue>12</issue>). <pub-id pub-id-type="doi">10.3390/biom9120789</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>M. J.</given-names></name><name><surname>Karadeniz</surname><given-names>F.</given-names></name><name><surname>Oh</surname><given-names>J. H.</given-names></name><name><surname>Yu</surname><given-names>G. H.</given-names></name><name><surname>Jang</surname><given-names>M. S.</given-names></name><name><surname>Nam</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>MMP-inhibitory Effects of Flavonoid Glycosides from Edible Medicinal Halophyte Limonium Tetragonum</article-title>. <source>Evid. Based Complement. Alternat Med.</source>
<volume>2017</volume>, <fpage>6750274</fpage>. <pub-id pub-id-type="doi">10.1155/2017/6750274</pub-id>
<pub-id pub-id-type="pmid">29234420</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D. S.</given-names></name><name><surname>Mellman</surname><given-names>I.</given-names></name></person-group> (<year>2017</year>). <article-title>Elements of Cancer Immunity and the Cancer-Immune Set point</article-title>. <source>Nature</source>
<volume>541</volume> (<issue>7637</issue>), <fpage>321</fpage>–<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1038/nature21349</pub-id>
<pub-id pub-id-type="pmid">28102259</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Indirubin Suppresses Ovarian Cancer Cell Viabilities through the STAT3 Signaling Pathway</article-title>. <source>Drug Des. Devel Ther.</source>
<volume>12</volume>, <fpage>3335</fpage>–<lpage>3342</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S174613</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Mao</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Weng</surname><given-names>Q.</given-names></name><name><surname>Mao</surname><given-names>J.</given-names></name><name><surname>Ji</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>CRISPR-Cas9 for Cancer Therapy: Opportunities and Challenges</article-title>. <source>Cancer Lett.</source>
<volume>447</volume>, <fpage>48</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2019.01.017</pub-id>
<pub-id pub-id-type="pmid">30684591</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Counihan</surname><given-names>J. L.</given-names></name><name><surname>Grossman</surname><given-names>E. A.</given-names></name><name><surname>Nomura</surname><given-names>D. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Cancer Metabolism: Current Understanding and Therapies</article-title>. <source>Chem. Rev.</source>
<volume>118</volume> (<issue>14</issue>), <fpage>6893</fpage>–<lpage>6923</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00775</pub-id>
<pub-id pub-id-type="pmid">29939018</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Goeje</surname><given-names>P. L.</given-names></name><name><surname>Poncin</surname><given-names>M.</given-names></name><name><surname>Bezemer</surname><given-names>K.</given-names></name><name><surname>Kaijen-Lambers</surname><given-names>M. E. H.</given-names></name><name><surname>Groen</surname><given-names>H. J. M.</given-names></name><name><surname>Smit</surname><given-names>E. F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Induction of Peripheral Effector CD8 T-Cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients</article-title>. <source>Clin. Cancer Res.</source>
<volume>25</volume> (<issue>7</issue>), <fpage>2219</fpage>–<lpage>2227</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2243</pub-id>
<pub-id pub-id-type="pmid">30642911</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L. J.</given-names></name><name><surname>Qi</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Lei</surname><given-names>Y. H.</given-names></name><name><surname>Zhang</surname><given-names>D. M.</given-names></name><name><surname>Chen</surname><given-names>J. X.</given-names></name></person-group> (<year>2020</year>). <article-title>Natural Products and Their Derivatives: Promising Modulators of Tumor Immunotherapy</article-title>. <source>J. Leukoc. Biol.</source>
<volume>108</volume> (<issue>2</issue>), <fpage>493</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1002/JLB.3MR0320-444R</pub-id>
<pub-id pub-id-type="pmid">32678943</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dower</surname><given-names>C. M.</given-names></name><name><surname>Wills</surname><given-names>C. A.</given-names></name><name><surname>Frisch</surname><given-names>S. M.</given-names></name><name><surname>Wang</surname><given-names>H. G.</given-names></name></person-group> (<year>2018</year>). <article-title>Mechanisms and Context Underlying the Role of Autophagy in Cancer Metastasis</article-title>. <source>Autophagy</source>
<volume>14</volume> (<issue>7</issue>), <fpage>1110</fpage>–<lpage>1128</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2018.1450020</pub-id>
<pub-id pub-id-type="pmid">29863947</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fesnak</surname><given-names>A. D.</given-names></name><name><surname>June</surname><given-names>C. H.</given-names></name><name><surname>Levine</surname><given-names>B. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Engineered T Cells: the Promise and Challenges of Cancer Immunotherapy</article-title>. <source>Nat. Rev. Cancer</source>
<volume>16</volume> (<issue>9</issue>), <fpage>566</fpage>–<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2016.97</pub-id>
<pub-id pub-id-type="pmid">27550819</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>M. M.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Steliarova-Foucher</surname><given-names>E.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Cancer Incidence and Mortality Among Young Adults Aged 20-39 Years Worldwide in 2012: a Population-Based Study</article-title>. <source>Lancet Oncol.</source>
<volume>18</volume> (<issue>12</issue>), <fpage>1579</fpage>–<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30677-0</pub-id>
<pub-id pub-id-type="pmid">29111259</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>A.</given-names></name><name><surname>Raji</surname><given-names>I.</given-names></name><name><surname>Cinar</surname><given-names>B.</given-names></name><name><surname>Kucuk</surname><given-names>O.</given-names></name><name><surname>Oyelere</surname><given-names>A. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Design, Synthesis, and Evaluation of the Antiproliferative Activity of Hydantoin-Derived Antiandrogen-Genistein Conjugates</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>26</volume> (<issue>8</issue>), <fpage>1481</fpage>–<lpage>1487</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2018.01.009</pub-id>
<pub-id pub-id-type="pmid">29456113</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>F.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Curcumin Suppresses Proliferation and Migration of MDA-MB-231 Breast Cancer Cells through Autophagy-dependent Akt Degradation</article-title>. <source>PloS one</source>
<volume>11</volume> (<issue>1</issue>), <fpage>e0146553</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0146553</pub-id>
<pub-id pub-id-type="pmid">26752181</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>W. C.</given-names></name><name><surname>Bader</surname><given-names>J. S.</given-names></name><name><surname>Braun</surname><given-names>T. P.</given-names></name><name><surname>Califano</surname><given-names>A.</given-names></name><name><surname>Clemons</surname><given-names>P. A.</given-names></name><name><surname>Druker</surname><given-names>B. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An Expanded Universe of Cancer Targets</article-title>. <source>Cell</source>
<volume>184</volume> (<issue>5</issue>), <fpage>1142</fpage>–<lpage>1155</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.02.020</pub-id>
<pub-id pub-id-type="pmid">33667368</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinshaw</surname><given-names>D. C.</given-names></name><name><surname>Shevde</surname><given-names>L. A.</given-names></name></person-group> (<year>2019</year>). <article-title>The Tumor Microenvironment Innately Modulates Cancer Progression</article-title>. <source>Cancer Res.</source>
<volume>79</volume> (<issue>18</issue>), <fpage>4557</fpage>–<lpage>4566</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3962</pub-id>
<pub-id pub-id-type="pmid">31350295</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hisano</surname><given-names>Y.</given-names></name><name><surname>Hla</surname><given-names>T.</given-names></name></person-group> (<year>2019</year>). <article-title>Bioactive Lysolipids in Cancer and Angiogenesis</article-title>. <source>Pharmacol. Ther.</source>
<volume>193</volume>, <fpage>91</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.07.006</pub-id>
<pub-id pub-id-type="pmid">30048709</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>S. Y.</given-names></name><name><surname>Lee</surname><given-names>J. K.</given-names></name><name><surname>Jang</surname><given-names>E. H.</given-names></name><name><surname>Jeong</surname><given-names>S. Y.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Shikonin Blocks Migration and Invasion of Human Breast Cancer Cells through Inhibition of Matrix Metalloproteinase-9 Activation</article-title>. <source>Oncol. Rep.</source>
<volume>31</volume> (<issue>6</issue>), <fpage>2827</fpage>–<lpage>2833</lpage>. <pub-id pub-id-type="doi">10.3892/or.2014.3159</pub-id>
<pub-id pub-id-type="pmid">24789371</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Qiao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Licoricidin Inhibits the Growth of SW480 Human Colorectal Adenocarcinoma Cells <italic>In Vitro</italic> and <italic>In Vivo</italic> by Inducing Cycle Arrest, Apoptosis and Autophagy</article-title>. <source>Toxicol. Appl. Pharmacol.</source>
<volume>326</volume>, <fpage>25</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2017.04.015</pub-id>
<pub-id pub-id-type="pmid">28416456</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>J. B.</given-names></name><name><surname>Nam</surname><given-names>S. J.</given-names></name><name><surname>Yang</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Berberine Suppresses TNF-Alpha-Induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells</article-title>. <source>Molecules</source>
<volume>13</volume> (<issue>12</issue>), <fpage>2975</fpage>–<lpage>2985</lpage>. <pub-id pub-id-type="doi">10.3390/molecules13122975</pub-id>
<pub-id pub-id-type="pmid">19052522</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopustinskiene</surname><given-names>D. M.</given-names></name><name><surname>Jakstas</surname><given-names>V.</given-names></name><name><surname>Savickas</surname><given-names>A.</given-names></name><name><surname>Bernatoniene</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Flavonoids as Anticancer Agents</article-title>. <source>Nutrients</source>
<volume>12</volume> (<issue>2</issue>). <pub-id pub-id-type="doi">10.3390/nu12020457</pub-id>
</mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Berberine Suppressed Epithelial Mesenchymal Transition through Cross-Talk Regulation of PI3K/AKT and RARα/RARβ in Melanoma Cells</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>479</volume> (<issue>2</issue>), <fpage>290</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.09.061</pub-id>
<pub-id pub-id-type="pmid">27639645</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Berberine-induced Autophagic Cell Death by Elevating GRP78 Levels in Cancer Cells</article-title>. <source>Oncotarget</source>
<volume>8</volume> (<issue>13</issue>), <fpage>20909</fpage>–<lpage>20924</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14959</pub-id>
<pub-id pub-id-type="pmid">28157699</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>T. S.</given-names></name><name><surname>Chan</surname><given-names>L. K. Y.</given-names></name><name><surname>Man</surname><given-names>G. C. W.</given-names></name><name><surname>Wong</surname><given-names>C. H.</given-names></name><name><surname>Lee</surname><given-names>J. H. S.</given-names></name><name><surname>Yim</surname><given-names>S. F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-dependent Exocytosis</article-title>. <source>Cancer Immunol. Res.</source>
<volume>8</volume> (<issue>8</issue>), <fpage>1099</fpage>–<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-19-0616</pub-id>
<pub-id pub-id-type="pmid">32354736</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Antitumor Activity of Curcumin by Modulation of Apoptosis and Autophagy in Human Lung Cancer A549 Cells through Inhibiting PI3K/Akt/mTOR Pathway</article-title>. <source>Oncol. Rep.</source>
<volume>39</volume> (<issue>3</issue>), <fpage>1523</fpage>–<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6188</pub-id>
<pub-id pub-id-type="pmid">29328421</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Arctigenin, a Lignan from Arctium Lappa L., Inhibits Metastasis of Human Breast Cancer Cells through the Downregulation of MMP-2/-9 and Heparanase in MDA-MB-231 Cells</article-title>. <source>Oncol. Rep.</source>
<volume>37</volume> (<issue>1</issue>), <fpage>179</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.3892/or.2016.5269</pub-id>
<pub-id pub-id-type="pmid">27878294</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>N.</given-names></name><name><surname>Rosenthal</surname><given-names>R.</given-names></name><name><surname>Hiley</surname><given-names>C. T.</given-names></name><name><surname>Rowan</surname><given-names>A. J.</given-names></name><name><surname>Watkins</surname><given-names>T. B. K.</given-names></name><name><surname>Wilson</surname><given-names>G. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution</article-title>. <source>Cell</source>
<volume>171</volume> (<issue>6</issue>), <fpage>1259</fpage>–<lpage>e11</lpage>. <comment>e1211</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.10.001</pub-id>
<pub-id pub-id-type="pmid">29107330</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>V.</given-names></name></person-group> (<year>2018</year>). <article-title>Epithelial Mesenchymal Transition in Tumor Metastasis</article-title>. <source>Annu. Rev. Pathol.</source>
<volume>13</volume>, <fpage>395</fpage>–<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathol-020117-043854</pub-id>
<pub-id pub-id-type="pmid">29414248</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadlou</surname><given-names>M.</given-names></name><name><surname>Abdollahi</surname><given-names>M.</given-names></name><name><surname>Hemati</surname><given-names>M.</given-names></name><name><surname>Baharlou</surname><given-names>R.</given-names></name><name><surname>Doulabi</surname><given-names>E. M.</given-names></name><name><surname>Pashaei</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Apoptotic Effect of Berberine via Bcl-2, ROR1, and Mir-21 in Patients with B-Chronic Lymphocytic Leukemia</article-title>. <source>Phytother Res.</source>
<volume>35</volume> (<issue>4</issue>), <fpage>2025</fpage>–<lpage>2033</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6945</pub-id>
<pub-id pub-id-type="pmid">33174291</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohan</surname><given-names>V.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>R. P.</given-names></name></person-group> (<year>2016</year>). <article-title>A Novel Alkaloid, Evodiamine Causes Nuclear Localization of Cytochrome-C and Induces Apoptosis Independent of P53 in Human Lung Cancer Cells</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>477</volume> (<issue>4</issue>), <fpage>1065</fpage>–<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.07.037</pub-id>
<pub-id pub-id-type="pmid">27402273</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondal</surname><given-names>A.</given-names></name><name><surname>Gandhi</surname><given-names>A.</given-names></name><name><surname>Fimognari</surname><given-names>C.</given-names></name><name><surname>Atanasov</surname><given-names>A. G.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Alkaloids for Cancer Prevention and Therapy: Current Progress and Future Perspectives</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>858</volume>, <fpage>172472</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172472</pub-id>
<pub-id pub-id-type="pmid">31228447</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palermo</surname><given-names>C. M.</given-names></name><name><surname>Westlake</surname><given-names>C. A.</given-names></name><name><surname>Gasiewicz</surname><given-names>T. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Epigallocatechin Gallate Inhibits Aryl Hydrocarbon Receptor Gene Transcription through an Indirect Mechanism Involving Binding to a 90 kDa Heat Shock Protein</article-title>. <source>Biochemistry</source>
<volume>44</volume> (<issue>13</issue>), <fpage>5041</fpage>–<lpage>5052</lpage>. <pub-id pub-id-type="doi">10.1021/bi047433p</pub-id>
<pub-id pub-id-type="pmid">15794642</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S. S.</given-names></name><name><surname>Acharya</surname><given-names>A.</given-names></name><name><surname>Ray</surname><given-names>R. S.</given-names></name><name><surname>Agrawal</surname><given-names>R.</given-names></name><name><surname>Raghuwanshi</surname><given-names>R.</given-names></name><name><surname>Jain</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Cellular and Molecular Mechanisms of Curcumin in Prevention and Treatment of Disease</article-title>. <source>Crit. Rev. Food Sci. Nutr.</source>
<volume>60</volume> (<issue>6</issue>), <fpage>887</fpage>–<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1080/10408398.2018.1552244</pub-id>
<pub-id pub-id-type="pmid">30632782</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasul</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Iqbal</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Magnolol, a Natural Compound, Induces Apoptosis of SGC-7901 Human Gastric Adenocarcinoma Cells via the Mitochondrial and PI3K/Akt Signaling Pathways</article-title>. <source>Int. J. Oncol.</source>
<volume>40</volume> (<issue>4</issue>), <fpage>1153</fpage>–<lpage>1161</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2011.1277</pub-id>
<pub-id pub-id-type="pmid">22139054</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>T.</given-names></name><name><surname>Sieglitz</surname><given-names>F.</given-names></name><name><surname>Bernardes</surname><given-names>G. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Natural Product Modulators of Transient Receptor Potential (TRP) Channels as Potential Anti-cancer Agents</article-title>. <source>Chem. Soc. Rev.</source>
<volume>45</volume> (<issue>22</issue>), <fpage>6130</fpage>–<lpage>6137</lpage>. <pub-id pub-id-type="doi">10.1039/c5cs00916b</pub-id>
<pub-id pub-id-type="pmid">26890476</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safarzadeh</surname><given-names>E.</given-names></name><name><surname>Sandoghchian Shotorbani</surname><given-names>S.</given-names></name><name><surname>Baradaran</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Herbal Medicine as Inducers of Apoptosis in Cancer Treatment</article-title>. <source>Adv. Pharm. Bull.</source>
<volume>4</volume> (<issue>Suppl. 1</issue>), <fpage>421</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.5681/apb.2014.062</pub-id>
<pub-id pub-id-type="pmid">25364657</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spradlin</surname><given-names>J. N.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Ward</surname><given-names>C. C.</given-names></name><name><surname>Brittain</surname><given-names>S. M.</given-names></name><name><surname>Jones</surname><given-names>M. D.</given-names></name><name><surname>Ou</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Harnessing the Anti-cancer Natural Product Nimbolide for Targeted Protein Degradation</article-title>. <source>Nat. Chem. Biol.</source>
<volume>15</volume> (<issue>7</issue>), <fpage>747</fpage>–<lpage>755</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-019-0304-8</pub-id>
<pub-id pub-id-type="pmid">31209351</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H. Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>J. N.</given-names></name><name><surname>Wang</surname><given-names>D. X.</given-names></name><name><surname>Xu</surname><given-names>Y. C.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Arsenic Trioxide Inhibits Liver Cancer Stem Cells and Metastasis by Targeting SRF/MCM7 Complex</article-title>. <source>Cell Death Dis</source>. <volume>10</volume> (<issue>6</issue>), <fpage>453</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-1676-0</pub-id>
<pub-id pub-id-type="pmid">31186405</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wimmer</surname><given-names>K.</given-names></name><name><surname>Sachet</surname><given-names>M.</given-names></name><name><surname>Oehler</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Circulating Biomarkers of Cell Death</article-title>. <source>Clin. Chim. Acta</source>
<volume>500</volume>, <fpage>87</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2019.10.003</pub-id>
<pub-id pub-id-type="pmid">31655053</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>S. M.</given-names></name><name><surname>Kwon</surname><given-names>T. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Jaceosidin Induces Apoptosis through Bax Activation and Down-Regulation of Mcl-1 and C-FLIP Expression in Human Renal Carcinoma Caki Cells</article-title>. <source>Chem. Biol. Interact</source>
<volume>260</volume>, <fpage>168</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2016.10.011</pub-id>
<pub-id pub-id-type="pmid">27729209</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Mu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Berberine Inhibits the Proliferation of colon Cancer Cells by Inactivating Wnt/β-Catenin Signaling</article-title>. <source>Int. J. Oncol.</source>
<volume>41</volume> (<issue>1</issue>), <fpage>292</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2012.1423</pub-id>
<pub-id pub-id-type="pmid">22469784</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>S.</given-names></name><name><surname>Eom</surname><given-names>G. H.</given-names></name></person-group> (<year>2016</year>). <article-title>HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases</article-title>. <source>Chonnam Med. J.</source>
<volume>52</volume> (<issue>1</issue>), <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.4068/cmj.2016.52.1.1</pub-id>
<pub-id pub-id-type="pmid">26865995</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. F.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>Y. H.</given-names></name><name><surname>Xu</surname><given-names>Z. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Systematic Elucidation of the Mechanism of Geraniol via Network Pharmacology</article-title>. <source>Drug Des. Devel Ther.</source>
<volume>13</volume>, <fpage>1069</fpage>–<lpage>1075</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S189088</pub-id>
</mixed-citation>
    </ref>
    <ref id="B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Jing</surname><given-names>Z.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Berberine Activates Caspase-9/cytochrome C-Mediated Apoptosis to Suppress Triple-Negative Breast Cancer Cells <italic>In Vitro</italic> and <italic>In Vivo</italic>
</article-title>. <source>Biomed. Pharmacother.</source>
<volume>95</volume>, <fpage>18</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.08.045</pub-id>
<pub-id pub-id-type="pmid">28826092</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Progress in Research on Paclitaxel and Tumor Immunotherapy</article-title>. <source>Cell Mol. Biol. Lett</source>. <volume>24</volume>, <fpage>40</fpage>. <pub-id pub-id-type="doi">10.1186/s11658-019-0164-y</pub-id>
<pub-id pub-id-type="pmid">31223315</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
